PAA-induced endothelial HIF-1α activation drives a gut‑vascular epigenetic memory that amplifies microbial dysbiosis and accelerates inflammaging

Lara Nielsen (PhD)· Mar 24, 2026

Mechanism: Gut-derived PAA stabilizes endothelial HIF-1α, driving lactate export that fuels PAA-producing bacteria and promotes systemic inflammaging via histone lactylation. Readout: Readout: Inhibiting endothelial HIF-1α or histone lactylation reduces lactate secretion, decreases PAA-producing bacteria, and lowers systemic inflammation.

Hypothesis

Phenylacetic acid (PAA) produced by gut microbes does more than trigger mitochondrial H₂O₂‑mediated endothelial senescence; it stabilizes HIF‑1α in endothelial cells even under normoxia, reprogramming their metabolism toward aerobic glycolysis and lactate export. This lactate‑rich microenvironment selectively fuels PAA‑producing bacteria in the gut, creating a self‑reinforcing loop that couples vascular metabolic reprogramming to microbiome aging. Consequently, endothelial HIF‑1α activation acts as an epigenetic ‘memory’ that translates a transient gut signal into persistent systemic inflammaging.

Rationale

PAA elevates mitochondrial ROS, which can inhibit prolyl hydroxylase domain (PHD) enzymes, reducing HIF‑1α degradation and promoting its nuclear accumulation—a mechanism documented in cancer and ischemia but not yet explored in endothelial senescence [1][2].
HIF‑1α drives transcription of glycolytic enzymes (GLUT1, LDHA) and lactate dehydrogenase A, increasing lactate secretion [3]. Elevated lactate lowers luminal pH and serves as a preferred carbon source for certain Clostridia that produce PAA [4].
Lactate also signaling through GPR81 on intestinal epithelial cells can tighten barrier function; however, chronic high lactate may desensitize this receptor, paradoxically increasing permeability and facilitating PAA translocation [5].
Endothelial HIF‑1α induces expression of adhesion molecules (ICAM‑1, VCAM‑1) and SASP components independent of senescence, amplifying leukocyte recruitment and inflammatory cytokine production [6].
Together, these actions suggest that PAA‑induced HIF‑1α activation creates a bidirectional metabolic‑inflammatory circuit: gut‑derived PAA → endothelial HIF‑1α → lactate efflux → enrichment of PAA‑producing microbes → more PAA.

Novel Mechanistic Insight

We propose that lactate exported by HIF‑1α‑activated endothelial cells acts as a metabolite messenger that remodels the gut niche, selectively expanding PAA‑synthesizing taxa. This metabolic cross‑talk establishes an epigenetic memory in endothelial cells via HIF‑1α‑mediated histone lactylation, sustaining a pro‑inflammatory transcriptional state even after PAA levels fluctuate.

Testable Predictions

Inhibition of endothelial HIF‑1α (using pharmacologic PHD activators or endothelial‑specific HIF‑1α siRNA) will reduce lactate secretion, lower luminal lactate levels, and decrease the relative abundance of PAA‑producing bacteria in aged mice.
Lactate supplementation to the gut lumen of young germ‑free mice colonized with a defined microbiota will increase the abundance of PAA‑producing Clostridia and elevate circulating PAA, recapitulating age‑associated endothelial senescence markers.
Blocking histone lactylation (with lactacystin or lactylo‑lysine antibodies) in endothelial cells will attenuate the SASP response to PAA without affecting HIF‑1α protein levels, indicating that lactylation sustains the inflammatory memory.
Adoptive transfer of serum lactate‑conditioned endothelial extracellular vesicles from aged to young mice will transplant the HIF‑1α‑dependent metabolic signature, accelerating gut barrier leakage and microbiome shifts.

Experimental Approach

Mouse models: Aged (24‑mo) C57BL/6J, endothelial‑specific HIF‑1α knockout (Tie2‑Cre;Hif1a^fl/fl), and germ‑free mice colonized with a synthetic human microbiome.
Interventions: Dimethyloxalylglycine (DMOG) to inhibit PHDs (positive control), and the PHD activator molidustatin (or its analog) to promote HIF‑1α degradation; lactate dehydrogenase inhibitor NHI‑2; lactylation inhibitor lactacystin.
Readouts:
- Plasma and fecal PAA (LC‑MS/MS).
- Endothelial HIF‑1α protein and lactate secretion (Western blot, Seahorse assay).
- Histone lactylation levels (anti‑lactyl‑lysine ChIP‑seq).
- Gut barrier integrity (FITC‑dextran permeability, claudin‑1/occludin immunofluorescence).
- Microbiome composition (16S rRNA sequencing, qPCR for PAA‑synthetase genes).
- Vascular senescence markers (SA‑β‑gal, p16^INK4a, SASP cytokines).
Statistical plan: Power analysis targeting n=8 per group for 80% power to detect a 30% change in PAA abundance; two‑way ANOVA with post‑hoc Tukey.

Potential Outcomes

If predictions hold: Demonstrates that endothelial HIF‑1α links gut metabolite signaling to microbiome remodeling, providing a mechanistic basis for the ‘microbial clock’ of aging. Therapeutic strategies targeting endothelial lactate export or histone lactylation could break the inflammaging loop independent of senolytics or BH₄ repletion.
If predictions fail: Would suggest that PAA’s effects are limited to direct oxidative senescence, prompting a refocus on mitochondrial ROS scavengers or microbiome‑targeted antibiotics as primary interventions.

Implications

This hypothesis reframes the gut‑brain‑vascular axis as a metabolite‑driven epigenetic circuit rather than a simple inflammatory cascade. It offers concrete, falsifiable nodes—endothelial HIF‑1α activity, lactate flux, and histone lactylation—that can be pharmacologically or genetically manipulated to test whether modulating the endothelial‑gut metabolic dialogue attenuates age‑related vascular and cognitive decline.

References

[1] https://lifespan.io/news/how-gut-microbiota-impact-endothelial-cell-senescence/ [2] https://doi.org/10.1101/2023.11.17.567594 [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC7384943/ [4] https://doi.org/10.1161/strokeaha.115.010835 [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC2781386/ [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC2921168/

Hypothesis

Rationale

PAA elevates mitochondrial ROS, which can inhibit prolyl hydroxylase domain (PHD) enzymes, reducing HIF‑1α degradation and promoting its nuclear accumulation—a mechanism documented in cancer and ischemia but not yet explored in endothelial senescence [1][2].

HIF‑1α drives transcription of glycolytic enzymes (GLUT1, LDHA) and lactate dehydrogenase A, increasing lactate secretion [3]. Elevated lactate lowers luminal pH and serves as a preferred carbon source for certain Clostridia that produce PAA [4].

Lactate also signaling through GPR81 on intestinal epithelial cells can tighten barrier function; however, chronic high lactate may desensitize this receptor, paradoxically increasing permeability and facilitating PAA translocation [5].

Endothelial HIF‑1α induces expression of adhesion molecules (ICAM‑1, VCAM‑1) and SASP components independent of senescence, amplifying leukocyte recruitment and inflammatory cytokine production [6].

Together, these actions suggest that PAA‑induced HIF‑1α activation creates a bidirectional metabolic‑inflammatory circuit: gut‑derived PAA → endothelial HIF‑1α → lactate efflux → enrichment of PAA‑producing microbes → more PAA.

Novel Mechanistic Insight

Testable Predictions

Inhibition of endothelial HIF‑1α (using pharmacologic PHD activators or endothelial‑specific HIF‑1α siRNA) will reduce lactate secretion, lower luminal lactate levels, and decrease the relative abundance of PAA‑producing bacteria in aged mice.

Lactate supplementation to the gut lumen of young germ‑free mice colonized with a defined microbiota will increase the abundance of PAA‑producing Clostridia and elevate circulating PAA, recapitulating age‑associated endothelial senescence markers.

Blocking histone lactylation (with lactacystin or lactylo‑lysine antibodies) in endothelial cells will attenuate the SASP response to PAA without affecting HIF‑1α protein levels, indicating that lactylation sustains the inflammatory memory.

Adoptive transfer of serum lactate‑conditioned endothelial extracellular vesicles from aged to young mice will transplant the HIF‑1α‑dependent metabolic signature, accelerating gut barrier leakage and microbiome shifts.

Experimental Approach

Mouse models: Aged (24‑mo) C57BL/6J, endothelial‑specific HIF‑1α knockout (Tie2‑Cre;Hif1a^fl/fl), and germ‑free mice colonized with a synthetic human microbiome.

Interventions: Dimethyloxalylglycine (DMOG) to inhibit PHDs (positive control), and the PHD activator molidustatin (or its analog) to promote HIF‑1α degradation; lactate dehydrogenase inhibitor NHI‑2; lactylation inhibitor lactacystin.

Readouts:

Plasma and fecal PAA (LC‑MS/MS).
Endothelial HIF‑1α protein and lactate secretion (Western blot, Seahorse assay).
Histone lactylation levels (anti‑lactyl‑lysine ChIP‑seq).
Gut barrier integrity (FITC‑dextran permeability, claudin‑1/occludin immunofluorescence).
Microbiome composition (16S rRNA sequencing, qPCR for PAA‑synthetase genes).
Vascular senescence markers (SA‑β‑gal, p16^INK4a, SASP cytokines).

Statistical plan: Power analysis targeting n=8 per group for 80% power to detect a 30% change in PAA abundance; two‑way ANOVA with post‑hoc Tukey.

Potential Outcomes

If predictions hold: Demonstrates that endothelial HIF‑1α links gut metabolite signaling to microbiome remodeling, providing a mechanistic basis for the ‘microbial clock’ of aging. Therapeutic strategies targeting endothelial lactate export or histone lactylation could break the inflammaging loop independent of senolytics or BH₄ repletion.

If predictions fail: Would suggest that PAA’s effects are limited to direct oxidative senescence, prompting a refocus on mitochondrial ROS scavengers or microbiome‑targeted antibiotics as primary interventions.

Implications